But one non-shareholding party will suffer from this setup. It is HM Treasury, which will be out of pocket to the tune of about £200m a year from lost stamp duty on transactions in London. Buyers of AstraZeneca shares in the UK, you see, will be getting a depositary interest in the company in future. It will carry the same voting and ownership rights as before but, critically, stamp duty does not apply to such instruments.